Business Context and Reporting Period
This Form 8-K was filed by Fluidigm Corporation (not Standard BioTools Inc.) on July 23, 2019. The report discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Base Annual Retainer: $40,000 for non-employee directors.
- Board Chair Retainer: Additional $50,000.
- Committee Compensation: Ranges from $5,000 to $10,000 annually depending on the committee.
- Initial Equity Grant: $55,000 value in stock options and $55,000 value in restricted stock units (RSUs) for the new director.
Material Changes
The Board of Directors increased its size from seven to eight members. Bill W. Colston, Ph.D., was appointed as a Class I director to fill the new vacancy. His term expires at the 2020 annual meeting of stockholders or until a successor is elected.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. It notes that Dr. Colston has entered into the Company's standard indemnification agreement. Future equity awards for Dr. Colston will align with terms for other continuing board members starting with the 2020 annual meeting.
Investor Verification Checklist
- Verify the correct registrant name is Fluidigm Corporation (ticker: FLDM), not Standard BioTools Inc.
- Confirm the total number of board seats is now eight.
- Review the vesting schedule for Dr. Colston's equity awards (four equal yearly installments).
- Check the attached press release (Exhibit 99.1) for additional context on the appointment.